<DOC>
	<DOC>NCT00715039</DOC>
	<brief_summary>The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.</brief_summary>
	<brief_title>Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Primary Diagnosis of GAD (DSM IV, 300.02) as established by the clinician using all sources of data including the MINI structured interview HAM A score ³20 at the Screening (Study Day 7) and Baseline (Study Day 1) Visits by observer rating Good health as determined by medical history, physical examination, vital signs, electrocardiography (ECG), and clinical laboratory measurements Covi Anxiety Scale total score ³9 and Raskin Depression Scale total score £7 at the Screening Visit (to ensure predominance of anxiety symptoms over depression symptoms) Age 18 to 65 (inclusive) Patients with most other current DSMIV Axis I disorders. Patients with current or past schizophrenia, Psychotic disorder Delirium, dementia, amnestic, and other clinically significant cognitive disorders Bipolar or schizoaffective disorder Benzodiazepine abuse or dependence; and/or Factitious disorder.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>generalized anxiety disorder</keyword>
	<keyword>onset of efficacy</keyword>
	<keyword>Daily Assessment of Symptoms-Anxiety (DAS-A)</keyword>
	<keyword>Methods</keyword>
</DOC>